United Capital Financial Advisors LLC Invests $1.29 Million in DexCom, Inc. $DXCM

Key Points

• United Capital Financial Advisors acquired 19,104 DexCom shares during the second quarter, valued at approximately $1.29 million. Institutional investors collectively own 97.75% of the company.
• DexCom reported quarterly EPS of $0.70, beating estimates by $0.09, while revenue rose 13.1% year over year to $1.31 billion. Shares opened at $90.82, near the company’s 12-month high of $92.59.
• Analysts maintain a generally positive outlook, with DexCom carrying a “Moderate Buy” consensus rating and an average price target of $88.71, although some firms recently downgraded or lowered their targets.

United Capital Financial Advisors LLC acquired a new stake in DexCom, Inc. (NASDAQ:DXCM - Free Report) during the 2nd quarter, according to its most recent disclosure with the SEC. The fund acquired 19,104 shares of the medical device company's stock, valued at approximately $1,287,000.

A number of other large investors have also recently added to or reduced their stakes in the company. Reflection Asset Management acquired a new position in DexCom during the fourth quarter worth $25,000. Ascentis Independent Advisors bought a new stake in DexCom during the 1st quarter worth about $25,000. MCF Advisors LLC bought a new stake in DexCom during the 4th quarter worth about $32,000. Wellington Grp LLC boosted its stake in shares of DexCom by 778.7% during the 1st quarter. Wellington Grp LLC now owns 536 shares of the medical device company's stock worth $34,000 after buying an additional 475 shares during the last quarter. Finally, DV Equities LLC acquired a new position in shares of DexCom during the 4th quarter worth about $36,000. Institutional investors own 97.75% of the company's stock.

Insider Transactions at DexCom

In related news, EVP Sadie Stern sold 2,565 shares of the firm's stock in a transaction dated Thursday, August 27th. The stock was sold at an average price of $88.37, for a total value of $226,669.05. Following the sale, the executive vice president directly owned 126,043 shares of the company's stock, valued at $11,138,419.91. This trade represents a 1.99% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kevin R. Sayer sold 26,756 shares of the firm's stock in a transaction dated Monday, July 20th. The shares were sold at an average price of $76.32, for a total value of $2,042,017.92. Following the completion of the sale, the insider directly owned 328,970 shares in the company, valued at $25,106,990.40. This trade represents a 7.52% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 75,600 shares of company stock worth $5,673,342. 0.28% of the stock is owned by insiders.

DexCom Price Performance

Shares of NASDAQ:DXCM opened at $90.82 on Friday. The firm has a 50 day moving average of $79.21 and a 200-day moving average of $71.60. DexCom, Inc. has a 12 month low of $54.11 and a 12 month high of $92.59. The company has a current ratio of 1.73, a quick ratio of 1.43 and a debt-to-equity ratio of 0.47. The stock has a market capitalization of $34.27 billion, a PE ratio of 35.90, a PEG ratio of 1.53 and a beta of 1.41.

DexCom (NASDAQ:DXCM - Get Free Report) last posted its quarterly earnings results on Thursday, July 30th. The medical device company reported $0.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.61 by $0.09. The business had revenue of $1.31 billion for the quarter, compared to analyst estimates of $1.29 billion. DexCom had a net margin of 20.12% and a return on equity of 35.94%. The firm's revenue for the quarter was up 13.1% on a year-over-year basis. During the same quarter last year, the business posted $0.48 EPS. On average, equities research analysts predict that DexCom, Inc. will post 2.64 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms recently weighed in on DXCM. Wall Street Zen cut shares of DexCom from a "buy" rating to a "hold" rating in a research note on Saturday. Barclays reiterated an "underweight" rating and issued a $64.00 price target (down from $67.00) on shares of DexCom in a research note on Monday, May 18th. Mizuho lifted their price objective on shares of DexCom from $90.00 to $95.00 and gave the company an "outperform" rating in a research report on Friday, July 31st. Piper Sandler restated an "overweight" rating and set a $95.00 price objective (up from $88.00) on shares of DexCom in a research note on Friday, July 31st. Finally, Citigroup reaffirmed a "buy" rating and issued a $88.00 target price (up from $84.00) on shares of DexCom in a report on Friday, July 31st. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, DexCom currently has an average rating of "Moderate Buy" and an average price target of $88.71.

DexCom Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company's offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source